Bloomberg Law
Sept. 25, 2020, 10:03 AMUpdated: Sept. 25, 2020, 4:17 PM

Ginsburg Death Threatens Biosimilars in Looming Obamacare Case (1)

Valerie Bauman
Valerie Bauman

The system that allows for low-cost versions of biologic drugs is in peril if Obamacare is reversed in the wake of Justice Ruth Bader Ginsburg’s death.

The Affordable Care Act created a pathway for companies to make biosimilars—generic versions of biologic drugs that are very similar, though not identical, to the originals—without having to jump through costly hoops associated with getting a novel medicine approved.

Biologic drugs are produced from living organisms or contain components thereof to create effective therapies. For example, AbbVie Inc.'s Humira is a biologic that treats conditions such as rheumatoid arthritis and Crohn’s Disease, while Genentech ...

Learn more about Bloomberg Law or Log In to keep reading:

Learn About Bloomberg Law

AI-powered legal analytics, workflow tools and premium legal & business news.

Already a subscriber?

Log in to keep reading or access research tools.